{"id":32662,"date":"2025-04-29T12:34:45","date_gmt":"2025-04-29T04:34:45","guid":{"rendered":"https:\/\/flcube.com\/?p=32662"},"modified":"2025-04-29T12:34:46","modified_gmt":"2025-04-29T04:34:46","slug":"shanghai-pharmaceuticals-posts-modest-q1-revenue-growth-sees-profit-decline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32662","title":{"rendered":"Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline"},"content":{"rendered":"\n<p>China&#8217;s Shanghai Pharmaceuticals (SPH, <a href=\"https:\/\/www.google.com\/finance\/quote\/2607:HKG\">HKG: 2607<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/601607:SHA\">SHA: 601607<\/a>) released its Q1 2025 financial results, showing total revenues increased by 0.87% year-on-year (YOY) to RMB 70.763 billion (USD 9.7 billion). Within this, the pharmaceutical industry and pharmaceutical business achieved sales of RMB 5.885 billion (USD 808.74 million) and RMB 6.4878 billion (USD 8.916 billion), respectively.<\/p>\n\n\n\n<p><strong>Net Profit and Sector Performance<\/strong><br>During the quarter, net profit attributable to shareholders of the listed company decreased by 13.56% YOY to RMB 1.333 billion (USD 183.2 million). The industrial sector, commercial sector, and major subsidiaries contributed profits of RMB 532 million (USD 73 million), RMB 834 million (USD 115 million), and RMB 196 million (USD 27 million), respectively. The net profit attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was RMB 1.263 billion (USD 174 million).<\/p>\n\n\n\n<p><strong>Research and Development Investment<\/strong><br>During the reporting period, Shanghai Pharmaceuticals invested RMB 612 million (USD 84 million) in research and development, underscoring its commitment to innovation and growth.<\/p>\n\n\n\n<p><strong>Business Segment Performance<\/strong><br>The company maintained growth momentum in several key areas during the quarter:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Import Agents<\/strong>: Sales revenue from the import general agency business reached RMB 8.6 billion (USD 1.3 billion) after a 9.0% expansion.<\/li>\n\n\n\n<li><strong>Innovative Drug Services<\/strong>: The innovative pharmaceutical business achieved sales revenue of RMB 12.5 billion (USD 1.7 billion), up 23.2% YOY.<\/li>\n\n\n\n<li><strong>CSO and Equipment Business<\/strong>: The drug CSO business revenue increased by 9.89% YOY. The sales revenue of the equipment health business reached RMB 10.9 billion (USD 1.5 billion), up 6.9% YOY.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/601607_20250429_92KU.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 601607_20250429_92KU.\"><\/object><a id=\"wp-block-file--media-793562d7-c873-4eca-8fdf-240e75721685\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/601607_20250429_92KU.pdf\">601607_20250429_92KU<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/601607_20250429_92KU.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-793562d7-c873-4eca-8fdf-240e75721685\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32665,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,890,891,196],"class_list":["post-32662","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-2607","tag-sha-601607","tag-shanghai-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing total revenues increased by 0.87% year-on-year (YOY) to RMB 70.763 billion (USD 9.7 billion). Within this, the pharmaceutical industry and pharmaceutical business achieved sales of RMB 5.885 billion (USD 808.74 million) and RMB 6.4878 billion (USD 8.916 billion), respectively.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32662\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline\" \/>\n<meta property=\"og:description\" content=\"China&#039;s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing total revenues increased by 0.87% year-on-year (YOY) to RMB 70.763 billion (USD 9.7 billion). Within this, the pharmaceutical industry and pharmaceutical business achieved sales of RMB 5.885 billion (USD 808.74 million) and RMB 6.4878 billion (USD 8.916 billion), respectively.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32662\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-29T04:34:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-29T04:34:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2906.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32662#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32662\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline\",\"datePublished\":\"2025-04-29T04:34:45+00:00\",\"dateModified\":\"2025-04-29T04:34:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32662\"},\"wordCount\":235,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32662#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2906.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 2607\",\"SHA: 601607\",\"Shanghai Pharmaceuticals\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32662#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32662\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32662\",\"name\":\"Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32662#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32662#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2906.webp\",\"datePublished\":\"2025-04-29T04:34:45+00:00\",\"dateModified\":\"2025-04-29T04:34:46+00:00\",\"description\":\"China's Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing total revenues increased by 0.87% year-on-year (YOY) to RMB 70.763 billion (USD 9.7 billion). Within this, the pharmaceutical industry and pharmaceutical business achieved sales of RMB 5.885 billion (USD 808.74 million) and RMB 6.4878 billion (USD 8.916 billion), respectively.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32662#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32662\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32662#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2906.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2906.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32662#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline - Insight, China&#039;s Pharmaceutical Industry","description":"China's Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing total revenues increased by 0.87% year-on-year (YOY) to RMB 70.763 billion (USD 9.7 billion). Within this, the pharmaceutical industry and pharmaceutical business achieved sales of RMB 5.885 billion (USD 808.74 million) and RMB 6.4878 billion (USD 8.916 billion), respectively.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32662","og_locale":"en_US","og_type":"article","og_title":"Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline","og_description":"China's Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing total revenues increased by 0.87% year-on-year (YOY) to RMB 70.763 billion (USD 9.7 billion). Within this, the pharmaceutical industry and pharmaceutical business achieved sales of RMB 5.885 billion (USD 808.74 million) and RMB 6.4878 billion (USD 8.916 billion), respectively.","og_url":"https:\/\/flcube.com\/?p=32662","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-29T04:34:45+00:00","article_modified_time":"2025-04-29T04:34:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2906.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32662#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32662"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline","datePublished":"2025-04-29T04:34:45+00:00","dateModified":"2025-04-29T04:34:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32662"},"wordCount":235,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32662#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2906.webp","keywords":["Finanical Reports","HKG: 2607","SHA: 601607","Shanghai Pharmaceuticals"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32662#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32662","url":"https:\/\/flcube.com\/?p=32662","name":"Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32662#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32662#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2906.webp","datePublished":"2025-04-29T04:34:45+00:00","dateModified":"2025-04-29T04:34:46+00:00","description":"China's Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing total revenues increased by 0.87% year-on-year (YOY) to RMB 70.763 billion (USD 9.7 billion). Within this, the pharmaceutical industry and pharmaceutical business achieved sales of RMB 5.885 billion (USD 808.74 million) and RMB 6.4878 billion (USD 8.916 billion), respectively.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32662#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32662"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32662#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2906.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2906.webp","width":1080,"height":608,"caption":"Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32662#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2906.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32662"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32662\/revisions"}],"predecessor-version":[{"id":32666,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32662\/revisions\/32666"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32665"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}